Gain detailed insights into the trading activity of Congress members for BellRing Brands on our government trades page. Stay updated on how elected officials are investing in BRBR.

BellRing Brands - Government Trades

BellRing Brands

BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders, and nutrition bars. The company's products are distributed through a diverse network of channels including club, food, drug and mass, eCommerce, convenience and specialty.

Kellanova

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BRBR

Top 3 Defensive Stocks That May Keep You Up At Night This Month

Shopping basket with food

Long Ideas

Interview

SOVO

Food stocks &#34;have had a tough year,&#34; but snacking has been a good area within the sector, Gabelli Funds co-CIO Kevin Dreyer says.

Food Sector M&amp;A Is Heating Up, Gabelli Fund Manager Says: Watch For BellRing Brands, Campbell Soup

wall street chart shutter2

Intraday Update

Movers

BMRN

CSTL

New Oriental Education & Technology Group

KVUE

LUMN

MTRN

PLNT

SERV

TGTX

TMDX

VMEO

YUMC

Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

Health Care

ETFs

Advisors Series Trust VegTech Plant-based Innovation & Climate ETF

EATV

PSCC

USNA

Study shows no link between daily multivitamin use and lower risk of death in healthy adults. No difference in mortality from cancer, heart disease, or cerebrovascular diseases.

Multivitamins Show No Link To &#39;Lower Risk of Death,&#39; Study Finds

snacks

Analyst Color

Biotech

Equities

Sector ETFs

Retail Sales

Analyst Ratings

FTXG

MDLZ

Nestle Sponsored representing Registered Shares Series B

NSRGY

Food and beverage stocks endure their toughest week since May 2022, driven by concerns over weight-loss drugs and shifting consumer behavior.

Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise

Price Target

Reiteration

General

BellRing Brands Poised For Growth: Analyst Sees Supply Boost And Volume Gains Fueling 1H24 Performance

Mid Cap

Topics

POST

BellRing Brands Inc (NYSE: BRBR) caught the attention of Benzinga’s internal analyst Gianni Di Poce with its recent breakout from a descending triangle formation and subsequent new all-time highs.

Gianni Di Poce Rings The Bell On BellRing Brands, Calls For 42% Returns

Small Cap

COCO

The most overbought stocks in the consumer staples sector presents an opportunity to go short on these overvalued companies.

Top 5 Risk Off Stocks That May Crash In March

BRSP

NVAX

RIVN

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.


Novavax, AMC Entertainment And Other Big Stocks Moving Lower In Wednesday&#39;s Pre-Market Session

This Analyst Remains Bullish On BellRing Brands As Setup For FY23 Is &#39;Strong&#39;

BellRing Brands Inc

Brookline Capital analyst Kemp Dolliver downgrades Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) from Buy to Hold.

Downgrades

EYEN

Brookline Capital Downgrades Eyenovia to Hold

WIIM

ABUS

Barinthus Biotherapeutics shares are trading lower. The company announced data from the ongoing Phase 2b HBV003 clinical trial.

DBGI

Digital Brands Group shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year decline in Q3 revenue.

Citigroup analyst Keith Horowitz maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Buy and raises the price target from $50 to $55.

ALLY

Citigroup Maintains Buy on Ally Financial, Raises Price Target to $55

Investors with a lot of money to spend have taken a bearish stance on TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TDG, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for TransDigm Gr.
This isn't normal.
The overall sentiment of these big-money traders is split between 26% bullish and 60%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $1,689,007, and 3 are calls, for a total amount of $122,970.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $765.0 and $1325.0 for TransDigm Gr, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for TransDigm Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of TransDigm Gr's whale trades within a strike price range from $765.0 to $1325.0 in the last 30 days. 
<h3>TransDigm Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731694605_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$31.3</td>
<td>$30.6</td>
<td>$31.3</td>
<td>$1305.00</td>
<td>$356.8K</td>
<td align="right">121</td>
<td align="right">114</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$54.2</td>
<td>$52.0</td>
<td>$53.5</td>
<td>$1250.00</td>
<td>$292.5K</td>
<td align="right">0</td>
<td align="right">83</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$30.7</td>
<td>$29.0</td>
<td>$29.0</td>
<td>$1200.00</td>
<td>$287.1K</td>
<td align="right">4</td>
<td align="right">205</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$26.8</td>
<td>$22.4</td>
<td>$26.0</td>
<td>$1200.00</td>
<td>$252.2K</td>
<td align="right">4</td>
<td align="right">103</td>
</tr>
<tr>
<td>TDG</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.0</td>
<td>$11.2</td>
<td>$17.0</td>
<td>$1265.00</td>
<td>$170.0K</td>
<td align="right">34</td>
<td align="right">102</td>
</tr>
</tbody>
</table>

<h3>About TransDigm Gr</h3>
TransDigm manufactures and services a diverse set of specialized parts for commercial and military aircraft. The firm organizes itself in three segments: power and control, airframes, and a small non-aviation segment, which serves mostly off-road vehicles and mining equipment. It operates as an acquisitive holding company that focuses its portfolio on firms that make proprietary aerospace products with substantial aftermarket demand. TransDigm regularly employs financial leverage to amplify its operating results.
Having examined the options trading patterns of TransDigm Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of TransDigm Gr</h3>
<ul>
<li>With a trading volume of 236,246, the price of TDG is up by 1.44%, reaching $1290.0.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for TransDigm Gr</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $1531.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on TransDigm Gr with a target price of $1500. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on TransDigm Gr, which currently sits at a price target of $1563. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest TransDigm Gr options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

TransDigm Gr Unusual Options Activity

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are lower on Thursday due to<a href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers"> news </a>that President-elect Donald Trump picked Robert F. Kennedy Jr. as his next secretary of the Department of Health and Human Services. This has some investors concerned because Kennedy was critical of certain vaccines and vaccinations.
Some believe the weakness in the stock may present a buying opportunity. This is why our team of expert traders and technical analysts has made it our Stock of the Day.
On Wall Street, many trading strategies and methods are based on the concept of reversion to the mean. If something goes too far one way, there is a good chance that it reverses and comes back the other way.
Most of the time, a stock stays in what is known as its trading range. But sometimes investors and traders can become emotional and aggressive. They can push the shares out of the range.
When this happens, there may be opportunities to profit. There is a good chance there will be a reversion back to the mean.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1024x529.png" alt="" class="wp-image-650959" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1-1536x794.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15131422/Pfizer.1.png 1583w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill">WHO Calls Vaccines &#8216;Absolutely Critical&#8217; As Trump&#8217;s Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill</a>
If a stock is below its typical or average range, traders say that it is &#8220;oversold.&#8221; Some anticipate a reversal back to the average. This would mean a move higher.
So, they enter the market as buyers. This could put pressure on the stock and force the price higher. It could become a self-fulfilling prophecy.
The lower part of the chart is the Relative Strength Index (RSI) momentum indicator. When the blue line crosses below the horizontal red line, it indicates oversold conditions. As you can see, that is the case now. Pfizer is very oversold.
There is also another reason why the stock may reverse and head higher.
The shares have dropped to a price level that was support in April. Stocks tend to have support at levels that had been support before. Sometimes they can even rally off of support.
There are traders and investors who sold at the support level in April and regretted doing so when the price moved higher. Some decide to buy their shares back if they can at the same price they were sold.
So, now that the shares are back to their selling price, they are placing buy orders. This creates support.
The combination of being oversold and at support means there is a good chance Pfizer reverses and heads higher.
Read Next:<a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants"> </a> • <a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a>
Photo: Shutterstock

Technicals

Stock Of The Day: Is Pfizer Set Up To Rally?

Whales with a lot of money to spend have taken a noticeably bearish stance on Intuit.
Looking at options history for Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 28% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $224,213 and 9, calls, for a total amount of $436,947.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $560.0 to $730.0 for Intuit over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Intuit's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Intuit's significant trades, within a strike price range of $560.0 to $730.0, over the past month.
<h3>Intuit Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731694599_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$5.1</td>
<td>$4.2</td>
<td>$4.8</td>
<td>$730.00</td>
<td>$120.0K</td>
<td align="right">5</td>
<td align="right">451</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$89.7</td>
<td>$87.2</td>
<td>$89.6</td>
<td>$720.00</td>
<td>$71.6K</td>
<td align="right">4</td>
<td align="right">10</td>
</tr>
<tr>
<td>INTU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$94.7</td>
<td>$91.5</td>
<td>$94.7</td>
<td>$730.00</td>
<td>$66.2K</td>
<td align="right">9</td>
<td align="right">11</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$144.5</td>
<td>$140.9</td>
<td>$142.0</td>
<td>$560.00</td>
<td>$56.8K</td>
<td align="right">5</td>
<td align="right">2</td>
</tr>
<tr>
<td>INTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$81.7</td>
<td>$80.0</td>
<td>$80.42</td>
<td>$610.00</td>
<td>$56.2K</td>
<td align="right">80</td>
<td align="right">7</td>
</tr>
</tbody>
</table>

<h3>About Intuit</h3>
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of US market share for small-business accounting and do-it-yourself tax-filing software.
Having examined the options trading patterns of Intuit, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Intuit</h3>
<ul>
<li>Currently trading with a volume of 650,880, the INTU's price is down by -2.25%, now at $685.03. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>Professional Analyst Ratings for Intuit</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $800.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Intuit, targeting a price of $800. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Intuit with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

INTU

What the Options Market Tells Us About Intuit

Financial giants have made a conspicuous bullish move on Royal Caribbean Gr. Our analysis of options history for Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) revealed 11 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 27% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $238,532, and 8 were calls, valued at $709,157.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $240.0 for Royal Caribbean Gr, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Royal Caribbean Gr's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Royal Caribbean Gr's whale trades within a strike price range from $120.0 to $240.0 in the last 30 days. 
<h3>Royal Caribbean Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731694594_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$117.55</td>
<td>$116.0</td>
<td>$116.0</td>
<td>$120.00</td>
<td>$232.0K</td>
<td align="right">200</td>
<td align="right">20</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$26.15</td>
<td>$24.25</td>
<td>$25.2</td>
<td>$207.50</td>
<td>$136.0K</td>
<td align="right">185</td>
<td align="right">69</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$34.0</td>
<td>$31.9</td>
<td>$32.89</td>
<td>$200.00</td>
<td>$131.4K</td>
<td align="right">458</td>
<td align="right">40</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.2</td>
<td>$4.0</td>
<td>$4.2</td>
<td>$220.00</td>
<td>$126.0K</td>
<td align="right">633</td>
<td align="right">301</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.3</td>
<td>$4.15</td>
<td>$4.3</td>
<td>$220.00</td>
<td>$86.0K</td>
<td align="right">633</td>
<td align="right">538</td>
</tr>
</tbody>
</table>

<h3>About Royal Caribbean Gr</h3>
Royal Caribbean is the world's second-largest cruise company, operating 68 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021.
<h3>Present Market Standing of Royal Caribbean Gr</h3>
<ul>
<li>Currently trading with a volume of 665,083, the RCL's price is down by -0.86%, now at $231.0. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 76 days.</li>
</ul>
<h3>Professional Analyst Ratings for Royal Caribbean Gr</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $251.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Royal Caribbean Gr, which currently sits at a price target of $240. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Royal Caribbean Gr, targeting a price of $257. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Royal Caribbean Gr, targeting a price of $243. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Royal Caribbean Gr with a target price of $245. 
&#x2A; An analyst from Tigress Financial has decided to maintain their Buy rating on Royal Caribbean Gr, which currently sits at a price target of $270. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Royal Caribbean Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Royal Caribbean Gr's Options Market Dynamics

On Friday, Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company&#8217;s Optejet dispensing platform <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42004665/eyenovia-provides-update-on-phase-3-chaperone-study" rel="noreferrer noopener">pediatric progressive myopia</a>.
Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long.
The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting its primary endpoint of a less than 0.5 diopter progression in visual acuity over three years.
The DRC reviewed the safety and efficacy data from 252 evaluable patients. The DRC found that the rate of myopia progression was not significantly different between the two active treatment arms (0.01% and 0.1% atropine ophthalmic metered spray) and placebo.
In the safety analysis, all dosages and placebo appeared well-tolerated, with a mild and infrequent adverse event profile. Full study data has not yet been released to Eyenovia.
&#8220;We plan to terminate the study, review the data more thoroughly, and evaluate the next steps,&#8221; stated Michael Rowe, Eyenovia&#8217;s CEO.
In light of the results of this review, the company is considering strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives.
William Blair has downgraded <a target="_blank" href="https://www.benzinga.com/quote/EYEN/analyst-ratings" rel="noreferrer noopener">Eyenovia to Market Perform</a>.
The analyst says,&#8221; While the approval of Mydcombi provided important validation of Eyenovia's Optejet device, and the subsequent approval of clobetasol propionate ophthalmic solution 0.05% added another promising product to the company's commercial portfolio, we believe the negative results from the CHAPERONE study and limited capital to invest in the launch of clobetasol or further pipeline programs limits near-term upside.&#8221;
Price Action: EYEN stock is down 68.2% at $0.1083 at last check Friday.
Image via Unsplash
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42014448/teledyne-controls-eadl-xs-certified-for-boeing-737ng-aircraft-enhancing-data-security" target="_blank" rel="noreferrer noopener">Teledyne Controls&#8217; eADL XS Certified For Boeing 737NG Aircraft, Enhancing Data Security</a></li>
</ul>

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Avicanna Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTCQX">AVCNF</a>) announced its financial results Thursday for the third quarter, disclosing revenue of CA$6.27 million ($4.49 million), compared to CA$6.25 million in the same period last year. The Toronto-based cannabis company also reported improved consolidated gross margin to 57% from 46% for the same period in 2023.
"We are pleased to report the results of another quarter showing progressive improvements across our four business pillars," stated CEO Aras Azadian. "Our continuous optimization efforts contributed to improvements in our overall financial performance, consolidated gross margins, and balance sheet. We are now better positioned to turn our attention towards our international growth initiatives and take further steps towards advancing our long-term business model."
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41998220/agrifys-q3-revenue-drop-18-6m-loss-amid-new-leadership">Agrify&#8217;s Q3 Revenue Drop, $18.6M Loss Amid New Leadership</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Q3 Financial Highlights</h2>
<ul>
<li>Gross profit was CA$3.7 million compared to CA$2.9 million in the comparable quarter last year.</li>
</ul>
<ul>
<li>Adjusted EBITDA was a loss of CA$293,931 compared to adjusted EBITDA loss of $473,650 in the corresponding period last year.</li>
<li>Net loss amounted to CA$786,388 compared to net loss of CA$1.42 million in the third quarter of 2023.</li>
<li>Fully repaid outstanding principle balance of approximately CA$1.3 million owed under non-convertible debenture.</li>
</ul>
<h2 class="wp-block-heading">Recent Milestones</h2>
In August, the biopharmaceutical company&nbsp;announced &nbsp;the <a href="https://www.benzinga.com/markets/cannabis/24/08/40403052/avicannas-cbg-products-reach-19-countries-denmark-joins-global-expansion">successful export of its Aureus-branded cannabigerol (CBG) products to Denmark</a>. This marked the 19th international market for Aureus-branded products and the 22nd market overall for Avicanna&#8217;s product range. The export was facilitated through Avicanna's majority-owned subsidiary, Santa Marta Golden Hemp SAS.
The same month, Avicanna <a href="https://www.benzinga.com/markets/cannabis/24/08/40628172/avicanna-secures-nearly-2m-in-private-placement-deal-amid-us-patent-win-for-cannabinoid-topical-">closed a non-brokered private placement</a> offering of its 6,620,692 ‎‎units at $0.30 per unit for aggregate gross proceeds of $1,986,207.
This year also, the company confirmed that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 20230025693A1, covering the company&#8217;s deep penetrating topical cannabinoid composition and methods for <a href="https://www.benzinga.com/markets/cannabis/24/08/40585810/avicanna-secures-us-patent-for-topical-cannabinoid-technology-to-treat-pain-and-inflammation" target="_blank" rel="noreferrer noopener">treating musculoskeletal inflammation and pain.</a>
<h2 class="wp-block-heading">Price Action</h2>
Avicanna shares closed Thursday's market session flat at 17 cents a share.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41992549/cv-sciences-q3-revenue-stable-amid-new-launches-financing">CV Sciences Q3: Revenue Stable Amid New Launches, Financing</a></li>
</ul>
Photo: Courtesy of Avicanna

Cannabis

Earnings

AVCNF

Avicanna Reduces Net Loss And Improves Gross Profit, Focusing On International Markets

Money is one of the top reasons couples fight – and when one partner hasn't worked for over a decade, tensions only rise. This was the case for a woman who recently called into financial advisor <a href="https://www.benzinga.com/personal-finance/24/11/41883704/start-with-a-beater-car-says-dave-ramsey-when-youre-debt-free-and-paying-cash-for-your-dream-ride-youll-appreciate-the-sacrifice">Dave Ramsey's show</a>, seeking advice on what to do about her husband, who's been unemployed for 13 years. Despite his Ph.D. in pharmaceutical chemistry, he hasn't held a job since his layoff in 2011, leaving her as the sole breadwinner.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/cd-valet-growth">CD Popularity Soars: Over 50 Million Americans Embrace Safe Savings with 5–10% Annual Growth</a></li>
</ul>
As she described how they'd moved across the country, sought counseling and even enlisted resume help, Ramsey listened closely before giving her some straight talk: "This has nothing to do with the mechanics of finding a job … He doesn't want to work."
The woman explained that her husband's layoff coincided with shifts in the pharmaceutical industry and the economic crash, which made finding a comparable job difficult. But, as she's rebuilt her career, she's increasingly felt that his job search has been less than active. Ramsey laid it out: "Behavior is a language. What's he been telling you for a decade? ‘I don't work.'"
Trending: Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a>
Co-host Dr. John Delony added that people in similar situations often take <a href="https://www.benzinga.com/startups/24/11/41852620/theres-a-great-place-to-go-when-youre-broke-to-work-says-dave-ramsey-about-a-piece-of-advice-he-got">whatever work they can find</a> to support their families. Ramsey pointed out, "I know too many people with Ph.D.s who got laid off but went to work at the grocery store or Walmart in the interim."
The caller admitted she'd encouraged him to find any job just to return to the workforce. Still, the years kept passing. Ramsey's co-host sympathized, but his message was tough: "This is about getting up off your butt." He continued, stressing that the woman's husband must feel the consequences of his inaction. "Somebody's going to have to love him enough to knock him out of the ditch," Ramsey advised, "because he ain't climbing out."
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
The situation became even trickier when she admitted she'd consulted a lawyer, only to find she might have to pay alimony if she left him. For this caller, Ramsey's advice boiled down to one central theme … love sometimes means <a href="https://www.benzinga.com/personal-finance/24/09/40838359/dave-ramsey-says-youre-wasting-5-000-a-year-if-you-spend-13-70-a-day-on-things-you-dont-need">helping someone face their reality</a>.
With the unemployment rate for Ph.D. holders aged 25 and over at just 1%, a 13-year gap in work is practically unheard of. According to Time, men without full-time jobs are 33% more likely to get divorced than those who are employed. So it's no wonder this caller is fed up with her husband's lack of ambition – her frustration is more than understandable.
Ramsey's advice cuts to the core. Without intervention, this <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">situation likely won't change</a> and the toll it takes on finances and marriage could grow harder to ignore.
Read Next:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

Woman Says Husband With A Ph.D. Hasn't Worked In 13 Years – Dave Ramsey Tells Her To 'Love Him Enough to Knock Him Out of the Ditch'

Citigroup analyst Alicia Yap maintains Dada Nexus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>) with a Neutral and lowers the price target from $2 to $1.9.

DADA

Citigroup Maintains Neutral on Dada Nexus, Lowers Price Target to $1.9

Citigroup analyst Alicia Yap maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Buy and raises the price target from $108 to $115.

NTES

Citigroup Maintains Buy on NetEase, Raises Price Target to $115

Citigroup analyst Alicia Yap maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Buy and lowers the price target from $52 to $51.

Citigroup Maintains Buy on JD.com, Lowers Price Target to $51

Alliance Global Partners analyst Gaurav Mehta downgrades Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) from Buy to Neutral and announces $2 price target.

SACH

Alliance Global Partners Downgrades Sachem Cap to Neutral, Announces $2 Price Target

<a href="https://www.politico.com/news/2024/11/15/trump-transition-steven-cheung-communications-director-00189857">https://www.politico.com/news/2024/11/15/trump-transition-steven-cheung-communications-director-00189857</a>
Steven Cheung, who served as Donald Trump's principal spokesperson on his 2024 campaign and also served on his 2020 and 2016 campaigns, is joining the White House as communications director, according to a person with direct knowledge of the matter.
Cheung has been a near constant presence at Trump's side and a key member of his tight-knit presidential campaign, run by Susie Wiles and Chris LaCivita.

Macro Economic Events

Politics

Economics

'Trump To Tap Campaign Spokesperson Steven Cheung As Communications Director' - Politico

Alliance Global Partners analyst Jeff Grampp maintains Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) with a Buy and lowers the price target from $7.5 to $5.5.

Alliance Global Partners Maintains Buy on Drilling Tools Intl, Lowers Price Target to $5.5

Econ #s

U.S. Baker Hughes Oil Rig Count -1 At 478; U.S. Baker Hughes NatGas Rig Count -1 At 101; U.S. Baker Hughes Total Rig Count 584 Vs 585 Prior

Wedbush analyst Andreas Argyrides reiterates Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Outperform and maintains $181 price target.

ASND

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $181 Price Target

Across the recent three months, 14 analysts have shared their insights on Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $22.36, a high estimate of $27.00, and a low estimate of $19.00. Experiencing a 10.31% decline, the current average is now lower than the previous average price target of $24.93. 
<img src="https://www.benzinga.com/files/images/story/2024/1731693679_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Couchbase is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Austin Dietz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Couchbase. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Couchbase compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Couchbase's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Couchbase's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BASE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Couchbase analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Couchbase: A Closer Look</h2>
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.
<h3>A Deep Dive into Couchbase's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Couchbase displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 19.59%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Couchbase's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -38.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Couchbase's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.56%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Couchbase's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.32%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Couchbase's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BASE

Navigating 14 Analyst Ratings For Couchbase

These are the mid-caps that could perform best during 'downturn' regimes – BofA

BellRing Brands: I Have A Healthy Growth Outlook For The Business

The Top Five long crowded stocks in each U.S. sector

Citi analyst Thomas Palmer maintained a Buy rating on BellRing Brands (BRBR – Research Report) today. The company's shares closed yesterday at $62....

BellRing Brands (BRBR) Receives a Buy from Citi

CPI read: Food inflation steps up in September as eggs, butter, and beef prices jump

Analyst Bryan Spillane of Bank of America Securities reiterated a Buy rating on BellRing Brands (BRBR – Research Report), with a price target of $7...

Strong Growth Potential for BellRing Brands: Buy Rating Backed by Expanding Market and Strategic Distribution

Analysts have been eager to weigh in on the Consumer Goods sector with new ratings on Altria Group (MO – Research Report) and BellRing Brands (BRBR...

Analysts Conflicted on These Consumer Goods Names: Altria Group (MO) and BellRing Brands (BRBR)

Barclays raised the firm's price target on BellRing Brands (BRBR) to $74 from $68 and keeps an Overweight rating on the shares. The firm continue t...

BellRing Brands price target raised to $74 from $68 at Barclays

Coty: With The Makeover Now Complete, This Prospect Is A Beauty

CPI read: Food prices ran below the overall inflation rate in October

ACGL

AKAM

BATRA

BATRK

BIPC

BOOT

BRFS

BWXT

CALM

CBOE

CELH

CHRW

CINF

COTY

DOLE

FRPT

FTAI

GATO

GOOD

HNST

IBKR

IMUX

INGR

IPAR

JJSF

KREF

KRON

LANC

MNDY

MNST

MTDR

NMRK

NWSA

OLLI

PNTG

PRAX

RBLX

ROST

RXST

RYAM

SHOP

SMPL

SMWB

SPOT

TTSH

TXRH

UBER

ZETA

ZUMZ

Management

Press Releases

BellRing Brands' Executive Chairman Rob Vitale Returns from Medical Leave

Government Trades

BellRing Brands Inc

top performing BRBR trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga